[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100314814":3},{"organization":4,"armGroups":7,"interventions":24,"overallOfficials":39,"centralContacts":44,"locations":23,"responsibleParty":50,"collaborators":23,"id":52,"slug":53,"hasResults":54,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":23,"eligibilityCriteria":58,"healthyVolunteers":54,"sex":59,"minAge":60,"maxAge":61,"enrollmentInfo":62,"targetDuration":23,"studyType":65,"phases":66,"briefSummary":68,"conditions":69,"keywords":74,"overallStatus":76,"whyStopped":23,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":23},{"fullName":5,"class":6},"Sclnow Biotechnology Co., Ltd.","INDUSTRY",[8,15,19],{"label":9,"type":10,"description":11,"interventionNames":12},"Intravenous infusion group","EXPERIMENTAL","Umbilical cord mesenchymal stem cells (SCLnow 19#)",[13,14],"Procedure: Intravenous infusion","Biological: umbilical cord mesenchymal stem cell",{"label":16,"type":10,"description":11,"interventionNames":17},"Intrathecal injection group",[18,14],"Procedure: Intrathecal injection",{"label":20,"type":21,"description":22,"interventionNames":23},"Control groups","NO_INTERVENTION","No intervention",null,[25,30,34],{"type":26,"name":27,"description":28,"armGroupLabels":29,"otherNames":23},"PROCEDURE","Intravenous infusion","Intravenous infusion of mesenchymal stem cells: 2 \\* 10\\^7 cells (30ml)",[9],{"type":26,"name":31,"description":32,"armGroupLabels":33,"otherNames":23},"Intrathecal injection","Intrathecal injection of mesenchymal stem cells: 2 \\* 10\\^7 cells (1ml)",[16],{"type":35,"name":36,"description":37,"armGroupLabels":38,"otherNames":23},"BIOLOGICAL","umbilical cord mesenchymal stem cell","Treat patients with umbilical cord mesenchymal stem cell (SCLnow 19#), the dosage based on different procedure",[16,9],[40],{"name":41,"affiliation":42,"role":43},"Hong Jiang","Xiangya Hospital of Central South University","PRINCIPAL_INVESTIGATOR",[45],{"name":46,"role":47,"phone":48,"phoneExt":23,"email":49},"Lei Guo","CONTACT","861064368977","georgeguo@sclnow.com",{"type":51,"investigatorFullName":23,"investigatorTitle":23,"investigatorAffiliation":23,"oldNameTitle":23,"oldOrganization":23},"SPONSOR","100314814","phase-2-umbilical-cord-mesenchymal-stem-cells-therapy-19isclife-sa-for-patients-with-spinocerebellar-ataxia-100314814",false,"NCT03378414","Umbilical Cord Mesenchymal Stem Cells Therapy (19#iSCLife®-SA) for Patients With Spinocerebellar Ataxia","A Clinical Research on the Safety\u002FEfficacy of Umbilical Cord Mesenchymal Stem Cells Therapy for Patients With Spinocerebellar Ataxia","Inclusion Criteria:\n\n* Clinical and genomic test diagnoses as spinocerebellar ataxias (SCA) (include SCA 1, SCA 2, SCA 3, SCA 6), SARA (Scale for Assessment and Rating of Ataxia) score is 2-5, can complete 8-meter walking test（8MW）\n* Do not receive stem cells treatment in 6 months\n* Participants sign the consent form based on the experiment process and statement\n\nExclusion Criteria:\n\n* Cardiac, renal, hepatic insufficiency; total bilirubin is 1.5 times higher than normal value, aspartate transaminase（AST）or alanine aminotransferase（ALT）is 2.5 times higher than normal value\n* Hemogram: total white blood cells \\\u003C3.0 \\* 10\\^9 cells\u002FL, blood platelet \\\u003C75 \\* 10\\^9\u002FL, hemoglobin \\\u003C100g\u002FL\n* pneumonia, or severe infection\n* With severe allergic history\n* Brain organic disorder, like brain tumor\n* Serum with HIV, syphilis antibody positive\n* Severe mental disease, cognitive disorder patients\n* Other severe system or organ organic disease\n* Pregnant, breast feeding, or planning pregnant women\n* Participate other clinical experiments in 3 months\n* With some other conditions that doctor propose not to participate","ALL","16 Years","60 Years",{"count":63,"type":64},45,"ESTIMATED","INTERVENTIONAL",[67],"PHASE2","The purpose of this study is verify the safety and efficacy of Human Umbilical Cord Mesenchymal Stem Cells (UC-MSC) therapy for patients with Spinocerebellar Ataxia, and in addition, explore the possible mechanisms of UC-MSC therapy in Spinocerebellar Ataxia.",[70,71,72,73],"Spinocerebellar Ataxia Type 1","Spinocerebellar Ataxia Type 2","Spinocerebellar Ataxia Type 3","Spinocerebellar Ataxia Type 6",[75],"Spinocerebellar Ataxia,Mesenchymal Stem Cells","NOT_YET_RECRUITING","2026-04-22",{"date":79,"type":80},"2026-04-23","ACTUAL",{"date":82,"type":64},"2026-12-31",{"date":84,"type":64},"2027-12-31",{"name":5,"class":6}]